Screening and identification of a renal carcinoma specific peptide from a phage display peptide library

Journal of Experimental & Clinical Cancer Research

Yuanyuan Zhang²  Shaopeng Qiu¹  Chunhua Deng¹  Jiquan Zhao¹  Liangyun Zhao¹  Liang Zhao¹  Wenwei Wang¹  Jintao Zhuang¹  Xiangan Tu¹ 

[1] Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, Guangdong, PR China;Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, NC, 27157, USA

关键词: Targeting;    Peptide;    Phage display;    Renal cell carcinoma;   

Others  :  827077
DOI  :  10.1186/1756-9966-30-105

 received in 2011-05-30, accepted in 2011-11-10,  发布年份 2011

【 摘 要 】

Background

Specific peptide ligands to cell surface receptors have been extensively used in tumor research and clinical applications. Phage display technology is a powerful tool for the isolation of cell-specific peptide ligands. To screen and identify novel markers for renal cell carcinoma, we evaluated a peptide that had been identified by phage display technology.

Methods

A renal carcinoma cell line A498 and a normal renal cell line HK-2 were used to carry out subtractive screening in vitro with a phage display peptide library. After three rounds of panning, there was an obvious enrichment for the phages specifically binding to the A498 cells, and the output/input ratio of phages increased about 100 fold. A group of peptides capable of binding specifically to the renal carcinoma cells were obtained, and the affinity of these peptides to the targeting cells and tissues was studied.

Results

Through a cell-based ELISA, immunocytochemical staining, immunohistochemical staining, and immunofluorescence, the Phage ZT-2 and synthetic peptide ZT-2 were shown to specifically bind to the tumor cell surfaces of A498 and incision specimens, but not to normal renal tissue samples.

Conclusion

A peptide ZT-2, which binds specifically to the renal carcinoma cell line A498 was selected from phage display peptide libraries. Therefore, it provides a potential tool for early diagnosis of renal carcinoma or targeted drug delivery in chemotherapy.

【 授权许可】

   
2011 Tu et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, CA Cancer. J Clin 2009 2009, 59(4):225-249.
• [2]Zhang J, Huang YR, Liu DM, Zhou LX, Xue W, Chen Q, Dong BJ, Pan JH, Xuan HQ: Management of solid renal tumour associated with von Hippel-Lindau disease. Chin Med J 2007, 120(22):2049-2052.
• [3]Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345(23):1655-1659.
• [4]Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 2005, 353(23):2477-2490.
• [5]Tunuguntla HS, Jorda M: Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol 2008, 179(6):2096-2102.
• [6]Eichelberg C, Junker K, Ljungberg B, Moch H: Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 2009, 55(4):851-863.
• [7]Pande J, Szewczyk MM, Grover AK: Phage display: concept, innovations, applications and future. Biotechnol Adv 2010, 28(6):849-858.
• [8]Barry MA, Dower WJ, Johnston SA: Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide presenting phage libraries. Nat Med 1996, 2(3):299-305.
• [9]Romanov VI, Durand DB, Petrenko VA: Phage-display selection of peptides that affect prostate carcinoma cells attachment and invasion. Prostate 2001, 47(4):239-251.
• [10]Shadidi M, Sioud M: Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J 2003, 17(2):256-258.
• [11]Du B, Qian M, Zhou ZL, Wang P, Wang L, Zhang X, Wu M, Zhang P, Mei B: In vitro panning of a targeting peptide to NCI-H1299 from a phage display peptide library. Biochem Biophys Res Comm 2006, 32(3):956-962.
• [12]Yang XA, Dong XY, Qiao H, Wang YD, Peng JR, Li Y, Pang XW, Tian C, Chen WF: Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues. Lab Invest 2005, 85(2):205-213.
• [13]Davis ID, Liu Z, Saunders W, Lee FT, Spirkoska V, Hopkins W, Smyth FE, Chong G, Papenfuss AT, Chappell B, Poon A, Saunder TH, Hoffman EW, Old LJ, Scott AM: A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun 2007, 7:13.
• [14]Xu C, Lo A, Yammanuru A, Tallarico AS, Brady K, Murakami A, Barteneva N, Zhu Q, Marasco WA: Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One 2010, 5(3):e9625.
• [15]Langer M, Beck-Sickinger AG: Peptides as carrier for tumor diagnosis and treatment. Curr Med Chem Anticancer Agents 2001, 1(1):71-93.